Natalizumab Risks and Benefits in Multiple Sclerosis
/
RSS Feed
Chris Polman, Free University of Amsterdam
Abstract N Engl J Med 2006;345:899
Despite fears that natalizumab – which reduces progression in some categories of patients with multiple sclerosis – might increased the risk of a fatal viral infection, two-year randomised study finding have now given some reassurance that patients with relapsing disease can be treated.
[audio:https://www.audiomedica.com/podcasting/news/chris_polman.mp3]
